Undergraduate School

B.S., Biology, University of the Philippines, Quezon City, Philippines 1987

Medical School

M.D., University of the Philippines College of Medicine, Manila, Philippines 1992

Internship

Internal Medicine, Rush Presbyterian-St Luke's Medical Center, Chicago IL 1993-1994

Internship

Multi-Departmental Rotation, University of the Philippines, Manila, Philippines 1991-1992

Residency

Internal Medicine, Rush Presbyterian-St Luke's Medical Center, Chicago IL 1994-1996

Fellowship

Hematology-Oncology, UC Davis School of Medicine, Sacramento CA 1996-1999

Best Doctors, SacTown Magazine, 2021

Best Doctors, Sacramento Magazine, 2020

Named one of the nation's Best Doctors in Oncology, 2011-present (Best Doctors Inc./Sacramento Magazine), 2021

Sacramento Magazine’s Top 300 Most Powerful Business Leaders, 2019

Faculty Research Award, UC Davis School of Medicine, Department of Internal Medicine, 2018

Kim JW, McKay RR, Radke MR, Zhao S, Taplin ME, Davis NB, Monk P, Appleman LJ, Lara PN Jr, Vaishampayan UN, Zhang J, Paul AK, Bubley G, Van Allen EM, Unlu S, Huang Y, Loda M, Shapiro GI, Glazer PM, LoRusso PM, Ivy SP, Shyr Y, Swisher EM, Petrylak DP. Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984. J Clin Oncol. 2023 Feb 1;41(4):871-880. doi:10.1200/JCO.21.02947. Epub 2022 Oct 18. PMID:36256912.

Yang JC, Xu P, Ning S, Wasielewski LJ, Adomat H, Hwang SH, Morisseau C, Gleave M, Corey E, Gao AC, Lara PN Jr, Evans CP, Hammock BD, Liu C. Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancer. Oncogene. 2023 Feb;42(9):693-707. doi:10.1038/s41388-022-02566-6. Epub 2023 Jan 3. PMID:36596844.

Sadeghi S, Quinn D, Dorff T, Pal S, Groshen S, Tsao-Wei D, Parikh R, Devitt M, Parikh M, Jackovich A, Ruel N, Vogelzang N, Burgess E, Siddiqi I, Gill IS, Lara PN, Dreicer R, Gill PS. EphrinB2 Inhibition and Pembrolizumab in Metastatic Urothelial Carcinoma. J Clin Oncol. 2023 Jan 20;41(3):640-650. doi:10.1200/JCO.21.02923. Epub 2022 Aug 19. PMID:35984996.

Gulati S, Lara PN. Immune Checkpoint Inhibitors in the Pre-operative Setting and Impact on the Primary Renal Tumor. Kidney Cancer. 2022 Dec 29;6(4):201-203. doi:10.3233/KCA-220019. PMID:36726555.

Cacciamani GE, Barzi A, Eppler MB, Lara PN Jr, Pan CX, Bhanvadia SK, Gill P, Aron M, Gill I, Sadeghi S. The Impact of Facility Surgical Caseload Volumes on Survival Outcomes in Patients Undergoing Radical Cystectomy. Cancers (Basel). 2022 Dec 3;14(23):5984. doi:10.3390/cancers14235984. PMID:36497466.

Woo XY, Srivastava A, Mack PC, Graber JH, Sanderson BJ, Lloyd MW, Chen M, Domanskyi S, Gandour-Edwards R, Tsai RA, Keck J, Cheng M, Bundy M, Jocoy EL, Riess JW, Holland W, Grubb SC, Peterson JG, Stafford GA, Paisie C, Neuhauser SB, Karuturi RKM, George J, Simons AK, Chavaree M, Tepper CG, Goodwin N, Airhart SD, Lara PN, Openshaw TH, Liu ET, Gandara DR, Bult CJ. A Genomically and Clinically Annotated Patient-Derived Xenograft Resource for Preclinical Research in Non-Small Cell Lung Cancer. Cancer Res. 2022 Nov 15;82(22):4126-4138. doi:10.1158/0008-5472.CAN-22-0948. PMID:36069866.

Leibrandt RC, Tu MJ, Yu AM, Lara PN, Parikh M. ATR Inhibition in Advanced Urothelial Carcinoma. Clin Genitourin Cancer. 2022 Nov 4:S1558-7673(22)00223-3. doi:10.1016/j.clgc.2022.10.016. Epub ahead of print. PMID:36604210.

Sjöström M, Zhao SG, Levy S, Zhang M, Ning Y, Shrestha R, Lundberg A, Herberts C, Foye A, Aggarwal R, Hua JT, Li H, Bergamaschi A, Maurice-Dror C, Maheshwari A, Chen S, Ng SWS, Ye W, Petricca J, Fraser M, Chesner L, Perry MD, Moreno-Rodriguez T, Chen WS, Alumkal JJ, Chou J, Morgans AK, Beer TM, Thomas GV, Gleave M, Lloyd P, Phillips T, McCarthy E, Haffner MC, Zoubeidi A, Annala M, Reiter RE, Rettig MB, Witte ON, Fong L, Bose R, Huang FW, Luo J, Bjartell A, Lang JM, Mahajan NP, Lara PN, Evans CP, Tran PT, Posadas EM, He C, Cui XL, Huang J, Zwart W, Gilbert LA, Maher CA, Boutros PC, Chi KN, Ashworth A, Small EJ, He HH, Wyatt AW, Quigley DA, Feng FY. The 5-Hydroxymethylcytosine Landscape of Prostate Cancer. Cancer Res. 2022 Nov 2;82(21):3888-3902. doi:10.1158/0008-5472.CAN-22-1123. PMID:36251389.

Parikh M, Lara PN. Evaluating the Optimal Duration of Immunotherapy in Kidney Cancer. Kidney Cancer. 2022 Aug 4;6(2):105-107. doi:10.3233/KCA-229003. PMID:36212798.

For a comprehensive list of Dr. Lara's publications, please click here.